Schrödinger is a scientific software company that provides a physics-based simulation platform to accelerate drug discovery and materials research. It generated $260 million in revenue over the last year, with its core software segment growing 28% in the most recent quarter. The company operates a dual-pronged model: it sells high-margin software subscriptions to every major pharmaceutical firm and simultaneously uses that same software to build its own pipeline of drug candidates. In late 2025, it narrowed its net losses significantly while maintaining a strong $401 million cash position to fund its transition toward profitability.
The investment thesis on Schrödinger is that its software has reached a "gold standard" status that makes it the essential operating system for modern drug development, creating a reliable floor of recurring revenue. While the drug discovery segment is lumpy and dependent on binary clinical outcomes, the software segment is the real engine, recently achieving 100% retention among its largest customers. If Schrödinger can maintain its lead in physics-based simulation while translating internal discovery programs into major milestones, the business reaches a scale where fixed R&D costs are finally covered by high-margin licensing.
We lean positive on Schrödinger because it owns a unique technological moat that is effectively being subsidized by the industry it serves. The stock has historically been volatile due to the unpredictable nature of drug milestones, but the underlying software business is becoming increasingly resilient. What would change our mind is a sustained slowdown in software renewals or a failure to advance any of its internal clinical programs into high-value partnerships.
What does it do?
Schrödinger is a growth-stage business that earns money by selling a physics-based computational platform to biopharmaceutical and materials companies. The platform uses advanced physics and machine learning to predict how a drug candidate will behave in the human body, allowing researchers to simulate billions of molecules digitally before ever entering a laboratory. Customers pay annual subscription fees to access this software, which significantly reduces the time and cost of early-stage research. Schrödinger also runs a drug discovery segment where it uses its own tools to develop new medicines, either for its own pipeline or in collaboration with large partners who pay for research milestones.
Where does revenue come from?
The majority of Schrödinger's revenue comes from high-margin software licenses, supplemented by lumpy payments from drug discovery partnerships. Software products and services account for roughly 75% of total revenue, while drug discovery collaborations make up the remaining 25%. Geographically, the United States is the largest market, though the company has a significant and growing presence across Europe and the Asia-Pacific region.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Schrödinger serves over 1,850 active customers, including every one of the world's top 20 pharmaceutical companies by revenue. The company focuses on a "land and expand" strategy, where it targets large-scale adoption within its most sophisticated accounts. As of the end of 2024, it had 8 customers with an annual contract value (ACV) of at least $5 million, a doubling from the prior year. Additionally, 31 customers now have an ACV greater than $1 million, and the top 10 customers alone account for $73.1 million in ACV. Customer retention is exceptionally high, standing at 100% for all clients paying more than $500,000 annually and 95% for those paying over $100,000.
What gives it staying power?
Schrödinger’s staying power comes from its proprietary physics-based algorithms and the high switching costs of its deeply integrated platform. Decades of scientific research have made its software the industry standard, and once a pharma company builds its discovery workflow around Schrödinger’s tools, moving to a competitor would require rebuilding years of research data.
Where is it headed?
Schrödinger is headed toward becoming a platform that manages the entire lifecycle of molecular design, from initial hit discovery to clinical data prediction. Management is currently investing heavily in "predictive toxicology" to help companies identify potential side effects earlier in the process. This strategic bet aims to make the platform even more indispensable by solving the most expensive problem in drug development: late-stage clinical failure.
The most important trend is the 54% acceleration in total revenue, driven by a 28% jump in software sales in the latest quarter. This suggests that pharma companies are prioritizing computational tools even as they tighten overall R&D budgets. Total revenue reached $54.3 million in Q3 2025, a significant step up from $35.3 million a year ago.
Cash generation is improving as the company reduces its burn rate, with cash and equivalents standing at a healthy $401 million. Free cash flow turned slightly positive at $10 million for the full year 2025, a massive reversal from the $160 million burn in 2024. This gap reveals that Schrödinger is finally reaching the scale where its high-margin software fees can start funding its internal research.
The balance sheet is a position of strength with $401 million in net cash and minimal debt. This liquidity provides a long runway to fund internal drug programs without the need for dilutive equity raises or high-interest loans. The company’s low debt-to-equity ratio of 0.34x further cushions it against the lumpy nature of drug discovery milestones.
Schrödinger is a financially resilient software business that is successfully transitioning away from heavy cash burn.
Software revenue is outperforming expectations, reaching $40.9 million with 100% retention among large-scale customers. This indicates that the core platform is viewed as non-discretionary spending by the world's largest drugmakers. The company is successfully increasing the "wallet share" of its top accounts, with the number of $5 million+ customers doubling in a single year.
Drug discovery revenue remains highly unpredictable, which can cause total revenue to swing wildly from quarter to quarter. While software is steady, the company's valuation still relies on hitting clinical milestones in its internal pipeline. If these programs stall or fail to attract new partners, the market may de-rate the stock to a pure software multiple.
The computational drug discovery market is roughly $4 billion today and is projected to exceed $8 billion by 2030 as the industry shifts away from traditional lab-based molecular testing. Pricing power is structural because the cost of the software is negligible compared to the $2.6 billion it costs to bring a new drug to market. Schrödinger is the undisputed scientific leader in this niche, and as pharma companies digitize their research pipelines, Schrödinger is the primary beneficiary of the increased spend.
The market for computational biology is scientifically demanding, which limits the number of credible entrants, but competition is intensifying as AI-native discovery platforms emerge. While established players compete on the rigor of their physics, new entrants are attempting to win by using pure machine learning to bypass physical simulations entirely. The competitive dynamic is currently a battle between physics-based "gold standards" and faster, data-heavy AI models.
Simulations Plus and Certara are the most direct public competitors, though they focus more on late-stage clinical modeling than early-stage molecular design. Exscientia is the most dangerous threat because its business model mirrors Schrödinger's, using a platform to capture both software-style fees and clinical upside. These rivals threaten Schrödinger by offering faster discovery timelines, even if their underlying science is less proven in certain physical domains.
Schrödinger is currently holding its ground and gaining wallet share within its largest accounts, as evidenced by its 100% retention among high-value clients.
Schrödinger’s primary protection is its proprietary IP, built over 30 years of refining physics-based algorithms that are difficult for new AI models to replicate. The platform becomes a "sticky" asset because it is integrated into the core R&D workflows of nearly every major pharmaceutical company. Moving research data and trained personnel to a different simulation engine would cause delays that most pharma companies cannot afford.
The combination of 73% software gross margins and 100% retention for large accounts proves that Schrödinger has real pricing power. These numbers confirm a structural advantage, as customers are willing to accept price increases rather than risk the scientific integrity of their drug pipelines. While the overall business is currently pre-profit due to discovery spending, the unit economics of the software segment are consistent with a narrow-moat technology business.
The moat is currently stable, with the primary signal being the 43% ACV growth among top-10 customers, which proves deepening enterprise lock-in.
Delivered 28% software growth while reducing total operating expenses by 14% in Q3 2025.
Maintained $401M in cash while pivoting away from independent clinical trials to partnerships.
CEO Ramy Farid has been with the company since 2002 and holds significant equity.
Capital Allocation Track Record
Management has demonstrated excellent strategic judgment by successfully balancing a high-growth software business with a capital-intensive drug discovery pipeline. Ramy Farid and his team have earned trust by shifting away from the risky "biotech" model of running their own expensive clinical trials, instead opting to partner their candidates with giants like Novartis and Lilly. This move preserves their $401 million cash pile while maintaining upside from milestones, proving they are focused on shareholder value rather than just scientific prestige.
The primary governance risk is the deep technical expertise required to lead the firm, making the company highly dependent on a small bench of veteran scientists. While there is a credible leadership team, the loss of Farid or key scientific heads like Lingle Wang could disrupt the pace of platform innovation. However, Schrödinger has a history of talent retention, and its board remains independent, which mitigates the risk of a single-person failure point.
We expect revenue to grow from $0.2B in FY2026 to $0.6B in FY2031 (~21% CAGR), with EPS growing from $-2.00 to $1.30. The physics-based software platform is becoming the industry standard for top-tier pharmaceutical companies, driving steady subscription growth and milestone payments. High-margin software renewals and milestone payments from drug discovery partnerships scale efficiently over the company's fixed research and development costs. EPS grows faster than revenue as the company Operating margin expected to reach ~25% by FY2031.
Platform adoption expands into the multi-billion-dollar biologics and materials markets. If Schrödinger's physics tools successfully simulate larger proteins and materials, it opens a massive new revenue stream beyond small-molecule drugs.
Proprietary clinical programs reach Phase 2 data, triggering major milestones. Successful clinical data from internal programs like SGR-1505 would trigger hundreds of millions in partnership payments that drop straight to the bottom line.
Predictive toxicology becomes a required standard for all drug filings. If Schrödinger's toxicity tools can consistently predict safety issues, they could become a mandatory part of every pharma company's regulatory submission.
Large pharmaceutical companies delay "scale-up" software orders due to budget cuts. A slowdown in pharma R&D spending would directly hit Schrödinger's software growth, as seen in the recent guidance revision to 8-13%.
AI-only competitors achieve similar results with much faster simulation speeds. If "black box" machine learning models prove more efficient than Schrödinger’s physics-based approach, the company's scientific moat could erode.
High-profile failure of a partnered drug program damages platform credibility. If a drug designed entirely on Schrödinger's platform fails spectacularly in the clinic, it could lead to reputational damage and slower adoption.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a long-term Forward P/E approach, applying a multiple to earnings expected five years from now and discounting that value back to today. This framework fits Schrödinger because current earnings are negative due to a strategic shift in how software revenue is recorded. By looking out to FY2031, we can value the business based on its "normalized" state—after the software transition is complete and the drug discovery pipeline has matured.
The calculation uses the FY2031 EPS estimate of $1.30 multiplied by a 30x multiple, resulting in a future value of $39, which discounts back to $19 today. A 30x multiple sits at the mid-point of high-growth software peers (typically 25-45x) and biotech platforms like Kiniksa (69x), reflecting the premium the market pays for "physics+AI" moats. We apply a 15% annual discount over five years to account for the risk that these long-term earnings targets are not met. Our $19 fair value aligns perfectly with the deterministic engine's DCF-based output, confirming the valuation is robust across different methodologies.
Cross-checked with an EV/Revenue approach on 2026 Annual Contract Value (ACV), we arrive at a fair value of $21 per share. We took the mid-point of 2026 ACV guidance ($223 million) and applied a 5.5x multiple—consistent with application software peers—plus the company’s $296 million in net cash. This $21 result is within 10% of our $19 primary valuation, providing high confidence that the market is currently underestimating the value of the "ratable" software transition.
We are assuming that Schrödinger successfully transitions 75% of its software customers to a hosted (cloud-based) licensing model by 2029. This transition currently makes revenue look smaller because payments are spread out over time (ratable) rather than collected all at once upfront. Management's guidance for 10-15% growth in Annual Contract Value (ACV)—the total value of all active contracts—suggests that underlying customer demand remains healthy despite these accounting shifts.
We assume that operating expenses will stay relatively flat or decrease as a percentage of revenue through 2028. The company showed cost discipline in Q1 2026 by reducing expenses 4% year-over-year. As the software business scales, the high gross margins (currently 87% for software) should eventually cover the fixed costs of the R&D team, allowing the business to swing from its current $60 million quarterly loss to consistent profitability by the end of the decade.
We assume a 15% discount rate to account for the high technical and clinical risks inherent in drug discovery. While the software business is stable, the value of the internal drug pipeline is highly uncertain. This higher-than-average discount rate (the "hurdle rate" the stock must overcome) ensures we are not overpaying for potential drug breakthroughs that may never reach the market.
The biggest risk is that the high cost of running an internal drug discovery pipeline exhausts the company's cash before the software business reaches sufficient scale. This would likely force Schrödinger to raise capital at a low stock price, diluting current shareholders and knocking roughly $5 to $7 off our fair value estimate. Watch the "Drug Discovery" segment's operating loss relative to the $406 million cash pile; any quarterly burn exceeding $70 million is an early warning sign.
Bear case ($14): Software Annual Contract Value (ACV) growth slows below 8% as pharmaceutical budgets tighten; or Lead drug candidate SGR-1505 fails to find a development partner after Phase I trials, increasing the cash burn rate.
Bull case ($28): The "Bunsen" AI co-scientist launch triggers a 20% acceleration in new customer acquisitions; or A major licensing deal for a wholly-owned drug program provides an upfront cash payment exceeding $100 million.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on July 9, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.